First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Alfred B. Tiono, Issa Nébié, Nicholas Anagnostou, Aboubacar S. Coulibaly, Georgina Bowyer, Erika Lam, Edith C. Bougouma, Alphonse Ouedraogo, Jean Baptist B. Yaro, Aïssata Barry, Rachel Roberts, Tommy Rampling, Carly Bliss, Susanne Hodgson, Alison Lawrie, Amidou Ouedraogo, Egeruan Babatunde Imoukhuede, Katie J. Ewer, Nicola K. Viebig, Amidou DiarraOdile Leroy, Philip Bejon, Adrian V.S. Hill, Sodiomon B. Sirima*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

Background Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified Vaccinia Virus Ankara (MVA) vectored vaccines is a strategy previously shown to provide substantial protective efficacy against P. falciparum infection in United Kingdom adult Phase IIa sporozoite challenge studies (approximately 20–25% sterile protection with similar numbers showing clear delay in time to patency), and greater point efficacy in a trial in Kenyan adults. Methodology We conducted the first Phase IIb clinical trial assessing the safety, immunogenicity and efficacy of ChAd63 MVA ME-TRAP in 700 healthy malaria exposed children aged 5–17 months in a highly endemic malaria transmission area of Burkina Faso. Results ChAd63 MVA ME-TRAP was shown to be safe and immunogenic but induced only moderate T cell responses (median 326 SFU/10 6 PBMC (95% CI 290–387)) many fold lower than in previous trials. No significant efficacy was observed against clinical malaria during the follow up period, with efficacy against the primary endpoint estimate by proportional analysis being 13.8% (95%CI -42.4 to 47.9) at sixth month post MVA ME-TRAP and 3.1% (95%CI -15.0 to 18.3; p = 0.72) by Cox regression. Conclusions This study has confirmed ChAd63 MVA ME-TRAP is a safe and immunogenic vaccine regimen in children and infants with prior exposure to malaria. But no significant protective efficacy was observed in this very highly malaria-endemic setting.

Original languageEnglish
Article numbere0208328
JournalPLoS ONE
Volume13
Issue number12
DOIs
Publication statusPublished - Dec 2018
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVVC), a 5-year integrated project (Grant number IP.2008.31100.001). The European Vaccine Initiative (EVI) was the coordinator of the EDCTP-funded MVVC project. Co-funding was also provided by the Swedish International Development Cooperation Agency (SIDA), the Austrian Federal Ministry of Science and Research, and Irish Aid. Additional support for the Oxford clinical trials team was provided by the UK NIHR through the Oxford Biomedical Research Centre. We thank the CNRFP staff at the Banfora research unit for their collaboration and C. McKenna for study Monitoring. We are thankful to the Data Safety Monitoring Board and all the study volunteers. We particularly note the contribution of Dr E B Imoukhuede, now sadly deceased, to this work.

Publisher Copyright:
© 2018 Tiono et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Fingerprint

Dive into the research topics of 'First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children'. Together they form a unique fingerprint.

Cite this